An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is a first-in human, open-label, Phase 1 dose-escalation study in order to determine the
maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for intravenous (IV)
and/or subcutaneous (SC) dosing schemes of this combination treatment, and to evaluate the
safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of this
combination treatment in participants with relapsed/refractory B-cell non Hodgkin lymphoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.